BRPI0620629B8 - composição farmacêutica, processo para preparar uma composição farmacêutica e seu uso - Google Patents
composição farmacêutica, processo para preparar uma composição farmacêutica e seu usoInfo
- Publication number
- BRPI0620629B8 BRPI0620629B8 BRPI0620629A BRPI0620629A BRPI0620629B8 BR PI0620629 B8 BRPI0620629 B8 BR PI0620629B8 BR PI0620629 A BRPI0620629 A BR PI0620629A BR PI0620629 A BRPI0620629 A BR PI0620629A BR PI0620629 B8 BRPI0620629 B8 BR PI0620629B8
- Authority
- BR
- Brazil
- Prior art keywords
- pharmaceutical composition
- preparing
- acid
- dihydroxypt
- methylsulfonyl
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 238000004519 manufacturing process Methods 0.000 title 1
- 239000002253 acid Substances 0.000 abstract 2
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 239000002775 capsule Substances 0.000 abstract 1
- 239000007857 degradation product Substances 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 239000008187 granular material Substances 0.000 abstract 1
- 150000002596 lactones Chemical class 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000003647 oxidation Effects 0.000 abstract 1
- 238000007254 oxidation reaction Methods 0.000 abstract 1
- 239000000843 powder Substances 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 239000000047 product Substances 0.000 abstract 1
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 239000003826 tablet Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SI200500344 | 2005-12-20 | ||
| SIP200500344 | 2005-12-20 | ||
| PCT/EP2006/012180 WO2007071357A2 (en) | 2005-12-20 | 2006-12-18 | Pharmaceutical composition comprising (e) -7- [4- (4-fluorophenyl) -6-isopropyl-2- [methyl (methylsulfonyl) amino] pyrimidin-5 -yl- (3r, 5s) -3, 5-dihydr0xyhept-6-en0ic acid |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BRPI0620629A2 BRPI0620629A2 (pt) | 2011-11-16 |
| BRPI0620629B1 BRPI0620629B1 (pt) | 2020-01-14 |
| BRPI0620629B8 true BRPI0620629B8 (pt) | 2021-05-25 |
Family
ID=37866173
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0620629A BRPI0620629B8 (pt) | 2005-12-20 | 2006-12-18 | composição farmacêutica, processo para preparar uma composição farmacêutica e seu uso |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20090093499A1 (enExample) |
| EP (1) | EP1968593B1 (enExample) |
| JP (1) | JP5235676B2 (enExample) |
| CN (1) | CN101330919B (enExample) |
| AU (1) | AU2006329006B2 (enExample) |
| BR (1) | BRPI0620629B8 (enExample) |
| CA (1) | CA2630704C (enExample) |
| EA (1) | EA015682B1 (enExample) |
| WO (1) | WO2007071357A2 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008036286A1 (en) | 2006-09-18 | 2008-03-27 | Teva Pharmaceutical Industries Ltd. | Crystalline rosuvastatin calcium |
| EP2285353A1 (en) * | 2008-01-30 | 2011-02-23 | Lupin Limited | Modified release formulations of hmg coa reductase inhibitors |
| EP2138165A1 (en) | 2008-06-27 | 2009-12-30 | KRKA, tovarna zdravil, d.d., Novo mesto | Pharmaceutical composition comprising a statin |
| HRP20180077T1 (hr) * | 2008-06-27 | 2018-02-23 | Krka, Tovarna Zdravil D.D., Novo Mesto | Farmaceutski sastav koji sadrži statin |
| PL386051A1 (pl) * | 2008-09-09 | 2010-03-15 | Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna | Stabilna doustna kompozycja farmaceutyczna zawierająca farmaceutycznie dopuszczalną sól kwsu [(E)-7-[4-(4-fluorofenylo)-6-izopropylo-2-[metylo(metylosulfonylo)amino]pirymidyn-5-ylo] (3R,5S)-3,5-dihydroksyhept-6-enowego |
| TR200902077A2 (tr) | 2009-03-17 | 2010-01-21 | Sanovel İlaç San.Veti̇c.A.Ş. | Stabil rosuvastatin kompozisyonları |
| RU2606592C1 (ru) * | 2015-10-07 | 2017-01-10 | Открытое Акционерное Общество "Татхимфармпрепараты" | Фармацевтическая композиция, содержащая кальциевую соль розувастатина (варианты) |
| AU2020417043A1 (en) * | 2019-12-31 | 2022-06-09 | Pfizer Inc. | Stable immediate release tablet and capsule formulations of 1-((2S,5R)-5-((7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2648897B2 (ja) * | 1991-07-01 | 1997-09-03 | 塩野義製薬株式会社 | ピリミジン誘導体 |
| GB0000710D0 (en) * | 1999-02-06 | 2000-03-08 | Zeneca Ltd | Drug combination |
| GB0001621D0 (en) * | 2000-01-26 | 2000-03-15 | Astrazeneca Ab | Pharmaceutical compositions |
| US6399101B1 (en) * | 2000-03-30 | 2002-06-04 | Mova Pharmaceutical Corp. | Stable thyroid hormone preparations and method of making same |
| EP1368000A4 (en) * | 2001-03-13 | 2004-12-01 | Penwest Pharmaceuticals Co | CHRONOTHERAPEUTIC PHARMACEUTICAL FORMS CONTAINING A GLUCOCORTICOSTEROID |
| SE0101329D0 (sv) * | 2001-04-12 | 2001-04-12 | Astrazeneca Ab | Pharmaceutical formulation |
| GB0111077D0 (en) * | 2001-05-04 | 2001-06-27 | Biochemie Gmbh | Organic compounds |
| US20030215502A1 (en) * | 2002-03-20 | 2003-11-20 | Elan Pharma International Limited | Fast dissolving dosage forms having reduced friability |
| WO2003090723A1 (en) * | 2002-04-23 | 2003-11-06 | Bristol-Myers Squibb Company | Modified-release vasopeptidase inhibitor formulation, combinations and method |
| CA2483099A1 (en) * | 2002-05-03 | 2003-11-13 | Hexal Ag | Stable pharmaceutical formulation for a combination of a statin and an ace inhibitor |
| SI21402A (sl) * | 2003-02-12 | 2004-08-31 | LEK farmacevtska dru�ba d.d. | Obloženi delci in farmacevtske oblike |
| WO2005040134A1 (en) * | 2003-10-22 | 2005-05-06 | Ranbaxy Laboratories Limited | Process for the preparation of amorphous rosuvastatin calcium |
| US8987322B2 (en) * | 2003-11-04 | 2015-03-24 | Circ Pharma Research And Development Limited | Pharmaceutical formulations for carrier-mediated transport statins and uses thereof |
| CA2546894C (en) * | 2003-12-02 | 2009-09-08 | Teva Pharmaceutical Industries Ltd. | Reference standard for characterization of rosuvastatin |
| EP1737828A1 (en) * | 2004-01-19 | 2007-01-03 | Ranbaxy Laboratories Limited | Amorphous magnesium salts of rosuvastatin |
| EP1709008A1 (en) * | 2004-01-19 | 2006-10-11 | Ranbaxy Laboratories Limited | Salts of hmg-coa reductase inhibitors and use thereof |
-
2006
- 2006-12-18 EP EP06829701.9A patent/EP1968593B1/en not_active Not-in-force
- 2006-12-18 WO PCT/EP2006/012180 patent/WO2007071357A2/en not_active Ceased
- 2006-12-18 CN CN2006800476115A patent/CN101330919B/zh not_active Expired - Fee Related
- 2006-12-18 CA CA2630704A patent/CA2630704C/en not_active Expired - Fee Related
- 2006-12-18 US US12/158,413 patent/US20090093499A1/en not_active Abandoned
- 2006-12-18 AU AU2006329006A patent/AU2006329006B2/en not_active Ceased
- 2006-12-18 EA EA200801447A patent/EA015682B1/ru not_active IP Right Cessation
- 2006-12-18 BR BRPI0620629A patent/BRPI0620629B8/pt not_active IP Right Cessation
- 2006-12-18 JP JP2008546216A patent/JP5235676B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CA2630704C (en) | 2014-08-19 |
| AU2006329006A1 (en) | 2007-06-28 |
| WO2007071357A2 (en) | 2007-06-28 |
| CN101330919B (zh) | 2012-12-05 |
| JP2009519985A (ja) | 2009-05-21 |
| BRPI0620629B1 (pt) | 2020-01-14 |
| CN101330919A (zh) | 2008-12-24 |
| BRPI0620629A2 (pt) | 2011-11-16 |
| WO2007071357A3 (en) | 2007-11-08 |
| JP5235676B2 (ja) | 2013-07-10 |
| US20090093499A1 (en) | 2009-04-09 |
| EA015682B1 (ru) | 2011-10-31 |
| CA2630704A1 (en) | 2007-06-28 |
| EA200801447A1 (ru) | 2008-12-30 |
| EP1968593B1 (en) | 2017-08-23 |
| AU2006329006B2 (en) | 2013-02-28 |
| EP1968593A2 (en) | 2008-09-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0715712B8 (pt) | composição farmacêutica adequada para a administração oral compreendendo um derivado de triazol[4,5d]pirimidina | |
| EA017764B8 (ru) | Фармацевтическая композиция, способ ее получения и способ лечения вирусных заболеваний с ее использованием | |
| AR023624A1 (es) | Composiciones farmaceuticas que comprenden un inhibidor de hmg coa reductasa | |
| BRPI0606883A2 (pt) | composição farmacêutica para administração oral, método para preparar um tablete, e, forma de dosagem sólida única | |
| EA201070841A1 (ru) | НОВЫЕ ПИРАЗОЛО[3,4-d]ПИРИМИДИНОВЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ПРОТИВОРАКОВЫХ ЛЕКАРСТВЕННЫХ СРЕДСТВ | |
| EA201100032A1 (ru) | Соединения пиридина | |
| TW200711652A (en) | Method and composition for pharmaceutical product | |
| CY1109457T1 (el) | Παραγωγο aminoαλκοολης ή παραγωγο φωσφονικου οξεος και φαρμακευτικη συνθεση που τα περιεχει | |
| CY1109756T1 (el) | Φαρμακευτικες συνθεσεις που περιεχουν κρυσταλλικα αλατα 7-[4-(4-φθοροφαινυλ)-6-ισοπροπυλ-2- [μεθυλ(μεθυλσουλφονυλ)αμινο] πυριμιδιν-5-υλ]-(3r,5s)-3,5-διυδροξυεπτ-6-ενοϊκου οξεος | |
| NZ595127A (en) | Stable pharmaceutical composition for atherosclerosis | |
| EA200901133A1 (ru) | Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение | |
| EA201490477A1 (ru) | Фармацевтические составы, содержащие пропиленгликоль-гидрат дапаглифлозина | |
| UA104988C2 (uk) | Похідні піроніндолу та спосіб їх отримання | |
| JO2973B1 (en) | Fumarate salt for (alpha-beta-R) -6-bromo-alpha-[2- (methylamino) ethyl-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinoline ethanol | |
| PH12019502566A1 (en) | Pharmacologically active alicyclic-substituted pyrazolo[1,5-a] pyrimidine derivatives | |
| ATE487720T1 (de) | 5,6,7,8-tetrahydropteridin-derivate als hsp90- hemmer | |
| BR112014011981A2 (pt) | formulações farmacêuticas | |
| WO2008074833A3 (en) | Compounds | |
| BRPI0514735B8 (pt) | derivados de pirimidino sulfonamida como moduladores do receptor de quimiocina. | |
| BRPI0620629B8 (pt) | composição farmacêutica, processo para preparar uma composição farmacêutica e seu uso | |
| MX2010004556A (es) | Formulacion farmaceutica de acido clavulanico. | |
| WO2010030201A3 (en) | Stable oral pharmaceutical composition containing a pharmaceutically acceptable salt of [(e)-7-[4-(4-fluorophenyl)-6-isopropyl-2- [methyl(methylsulfonyl)amino]pyrimidine-5-yl] (3r, 5s) - 3,5 dihydroxyhept-6- enoic acid | |
| BRPI0720251B8 (pt) | derivado de quinolina, sua composição farmacêutica, seu uso, combinação e produto compreendendo o mesmo | |
| AR022462A1 (es) | Uso de un agente que disminuye el colesterol | |
| TW201129557A (en) | Pharmaceutical composition for oral administration |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 14/01/2020, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 18/12/2006 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
| B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 16A ANUIDADE. |
|
| B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2703 DE 25-10-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |